Patrick A. Mayes, Ph.D.
Affiliations: | 2008 | University of Pennsylvania, Philadelphia, PA, United States |
Area:
Pharmacology, Oncology, Molecular BiologyGoogle:
"Patrick Mayes"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Wafik S. El-Deiry | grad student | 2008 | Penn | |
| (The mechanistic and therapeutic implications of tumor hypoxia in the TRAIL signaling pathway.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yadavilli S, Waight JD, Brett S, et al. (2023) Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade. Cancer Research Communications. 3: 1564-1579 |
| Montes de Oca R, Alavi AS, Vitali N, et al. (2021) Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-Mediated Anti-Tumor Responses In Vivo. Molecular Cancer Therapeutics |
| Allen JE, Krigsfeld G, Patel L, et al. (2015) Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Molecular Cancer. 14: 99 |
| Tai YT, Mayes PA, Acharya C, et al. (2014) Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 123: 3128-38 |
| Allen JE, Krigsfeld G, Mayes PA, et al. (2013) Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Science Translational Medicine. 5: 171ra17 |
| Mayes PA, Degenhardt YY, Wood A, et al. (2013) Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition. International Journal of Cancer. Journal International Du Cancer. 132: E149-57 |
| Tai Y, Acharya C, Zhong MY, et al. (2013) Novel Fc-Engineered Anti-B Cell Maturation Antigen-Monomethyl Auristatin F Antibody-Drug Conjugate (GSK2857916) Induces Potent and Selective Anti-Multiple Myeloma Activity Via Enhanced Effector Function and Direct Tumor Cell Killing Blood. 122: 877-877 |
| Qing G, Li B, Vu A, et al. (2012) ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell. 22: 631-44 |
| Dolloff NG, Mayes PA, Hart LS, et al. (2011) Off-target lapatinib activity sensitizes colon cancer cells through TRAIL death receptor up-regulation. Science Translational Medicine. 3: 86ra50 |
| Mayes PA, Dolloff NG, Daniel CJ, et al. (2011) Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1. Cancer Research. 71: 5265-75 |